In a remarkable turn of events, the contract research organization (CRO) sector witnessed an unprecedented surge in mergers and acquisitions (M&A) in 2021, defying the challenges posed by the Covid-19 pandemic. A staggering 50 M&A deals were successfully concluded, marking a substantial increase from the 29 deals recorded in 2020.
This surge can be attributed to a strategic shift among service providers, who opted to bolster their capabilities through M&A ventures rather than internally developing the same offerings.
Delve into the intricacies of this surge in M&A activities among CROs to gain invaluable insights into the dynamic forces reshaping the pharmaceutical landscape. Discover why industry leaders are strategically leveraging M&As and uncover the potential benefits for your own business endeavors.
Read the full article to stay ahead in the ever-evolving world of contract research organizations. https://www.clinicaltrialsarena.com/analysis/cro-mergers-impact-clinical-trial-sponsors/
Comments